6.56
price up icon7.19%   0.44
after-market After Hours: 6.72 0.16 +2.44%
loading
Wave Life Sciences Ltd stock is traded at $6.56, with a volume of 1.51M. It is up +7.19% in the last 24 hours and down -31.60% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$6.12
Open:
$6.13
24h Volume:
1.51M
Relative Volume:
1.33
Market Cap:
$963.89M
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-5.9099
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
+4.46%
1M Performance:
-31.60%
6M Performance:
-55.77%
1Y Performance:
+35.54%
1-Day Range:
Value
$6.13
$6.66
1-Week Range:
Value
$5.715
$6.75
52-Week Range:
Value
$4.25
$16.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name
Name
Wave Life Sciences Ltd
Name
Phone
617-949-2900
Name
Address
7 STRAITS VIEW, SINGAPORE
Name
Employee
288
Name
Twitter
@WAVELifeSci
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
WVE's Discussions on Twitter

Compare WVE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
WVE
Wave Life Sciences Ltd
6.56 963.89M 53.61M -142.52M -141.83M -1.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-08-25 Initiated Wedbush Outperform
Feb-25-25 Initiated Jefferies Buy
Oct-16-24 Upgrade Raymond James Outperform → Strong Buy
Sep-27-24 Resumed JP Morgan Overweight
Sep-19-24 Initiated B. Riley Securities Buy
Sep-09-24 Initiated JP Morgan Overweight
May-15-24 Initiated Wells Fargo Overweight
Dec-19-23 Upgrade Leerink Partners Market Perform → Outperform
Jul-05-23 Initiated Raymond James Outperform
May-24-23 Downgrade Jefferies Buy → Hold
Dec-15-20 Resumed H.C. Wainwright Buy
Oct-23-20 Initiated RBC Capital Mkts Sector Perform
Dec-31-19 Downgrade SVB Leerink Outperform → Mkt Perform
Nov-01-19 Initiated Guggenheim Buy
Jul-15-19 Initiated Cowen Market Perform
Apr-17-19 Reiterated H.C. Wainwright Buy
Aug-07-18 Initiated Stifel Buy
Jul-23-18 Initiated H.C. Wainwright Buy
Mar-19-18 Reiterated Mizuho Buy
Feb-15-17 Initiated H.C. Wainwright Buy
Nov-10-16 Resumed Leerink Partners Outperform
Dec-07-15 Initiated JMP Securities Mkt Outperform
Dec-07-15 Initiated Jefferies Buy
Dec-07-15 Initiated Leerink Partners Outperform
Dec-07-15 Initiated Sun Trust Rbsn Humphrey Buy
View All

Wave Life Sciences Ltd Stock (WVE) Latest News

pulisher
Apr 21, 2025

(WVE) Investment Report - news.stocktradersdaily.com

Apr 21, 2025
pulisher
Apr 15, 2025

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely? - Yahoo Finance

Apr 15, 2025
pulisher
Apr 13, 2025

Wave Life Sciences (NASDAQ:WVE) Earns Outperform Rating from Analysts at Wedbush - MarketBeat

Apr 13, 2025
pulisher
Apr 11, 2025

Wave Life Sciences (WVE) Price Target Reduced by B. Riley Amid F - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

B. Riley Adjusts Wave Life Sciences' Price Target to $19 From $22, Keeps Buy Rating - MarketScreener

Apr 10, 2025
pulisher
Apr 08, 2025

Wedbush sets $18 target for WAVE Life Sciences stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Wedbush sets $18 target for WAVE Life Sciences stock - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Wedbush Initiates Wave Life Sciences at Outperform With $18 Price Target - MarketScreener

Apr 08, 2025
pulisher
Apr 04, 2025

(WVE) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Apr 04, 2025

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st

Apr 04, 2025
pulisher
Apr 03, 2025

RBC Cuts Price Target on Wave Life Sciences to $10 From $14, Keeps Sector Perform, Speculative Risk - MarketScreener

Apr 03, 2025
pulisher
Mar 31, 2025

Wave Life Sciences’ SWOT analysis: RNA editing pioneer faces challenges in genetic medicine stock - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

What is Leerink Partnrs’ Estimate for WVE Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Promising Genomics & Synthetic Biology Stocks to Consider in 2025 - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Reaffirms “Buy” Rating for Wave Life Sciences (NASDAQ:WVE) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 (NASDAQ:WVE) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

WAVE Life Sciences stock holds buy rating, $22 target from H.C. Wainwright - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531 - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? - Nasdaq

Mar 27, 2025
pulisher
Mar 26, 2025

Wave Life Sciences reports progress in DMD treatment By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Aspires To Accelerated Approval In DMD With 48-Week Data - insights.citeline.com

Mar 26, 2025
pulisher
Mar 26, 2025

Riding the Wave, exon skipper sails toward DMD filing - BioWorld Online

Mar 26, 2025
pulisher
Mar 26, 2025

Sector Update: Health Care Stocks Retreat Wednesday Afternoon - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Jefferies maintains Buy on WAVE Life Sciences stock, $26 target By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences to submit Duchenne drug for approval after Phase 2 success - The Boston Globe

Mar 26, 2025
pulisher
Mar 26, 2025

Jefferies maintains Buy on WAVE Life Sciences stock, $26 target - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Wave to seek FDA accelerated approval for Duchenne candidate in 2026 - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences shares surge on positive DMD trial results By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences shares surge on positive DMD trial results - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences reports progress in DMD treatment - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences Reports Positive Phase 2 Trial Results - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Wave Life Sciences Announces Positive Data from FORWARD-53 - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Clinical Trial Breakthrough: New DMD Drug Achieves Unprecedented Muscle Recovery - StockTitan

Mar 26, 2025
pulisher
Mar 24, 2025

Victory Capital Management Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Charles Schwab Investment Management Inc. Grows Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Wave Life Sciences director Christian Henry sells $102,574 in shares By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Wave Life Sciences director Christian Henry sells $102,574 in shares - Investing.com

Mar 21, 2025
pulisher
Mar 20, 2025

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 20, 2025
pulisher
Mar 18, 2025

US Bancorp DE Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World

Mar 18, 2025
pulisher
Mar 16, 2025

Arizona State Retirement System Acquires 7,846 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

How To Trade (WVE) - Stock Traders Daily

Mar 15, 2025
pulisher
Mar 12, 2025

Wave Life Sciences’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Mizuho maintains WAVE Life Sciences Outperform rating By Investing.com - Investing.com India

Mar 11, 2025
pulisher
Mar 10, 2025

Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Paul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - Defense World

Mar 09, 2025

Wave Life Sciences Ltd Stock (WVE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Cap:     |  Volume (24h):